ANV419 + ipilimumab

ANV419 + ipilimumab is an investigational combination therapy for cancer that joins two immune-modulating agents. **ANV419** is a recombinant antibody–cytokine fusion protein consisting of human interleukin-2 (IL-2) linked to an anti-IL-2 monoclonal antibody. This design selectively stimulates the IL-2 receptor βγ subunits on effector T cells (especially CD8+ T cells) and natural killer (NK) cells, sparing immunosuppressive regulatory T cells. **Ipilimumab** is a fully human monoclonal antibody against CTLA-4 (cytotoxic T-lymphocyte–associated antigen 4) on T cells, functioning as a checkpoint inhibitor by blocking the negative regulation of T cell activity. This combination aims to drive potent antitumor responses by expanding effector lymphocytes (via ANV419) and simultaneously releasing immune suppression (via ipilimumab). Both drugs are administered intravenously. Primary clinical development is in advanced/refractory solid tumors, including melanoma, with the combination regimen under evaluation in the OMNIA-1 and ANV419-001 trials[1][3][5][7]. ANV419 is being developed by Anaveon; ipilimumab is developed and manufactured by Bristol Myers Squibb.

Other names

ANV419 + Yervoy